Icon snaps up molecular Dx specialist MolecularMD for undisclosed price

Laboratory
The purchase expands Icon’s laboratory offering in molecular diagnostic testing. (Getty/RossHelen)

Icon, a CRO based in Dublin, has acquired MolecularMD, a molecular diagnostic specialty lab that focuses on a platform for the development and commercialization of precision medicines for oncology.

Financial terms of the deal weren’t disclosed.

The purchase expands Icon’s laboratory offering in molecular diagnostic testing and brings expanded testing platforms, including next generation sequencing and immunohistochemistry (IHC), the company said.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

MolecularMD, which was founded in 2006, offers a comprehensive test menu in the area of immune oncology development at its labs in Portland, Oregon, and Cambridge, Massachusetts. The company also offers companion diagnostic development services.

“We are committed to expanding the testing we offer into specialized areas so that we can help customers to take time and cost from the development and commercialization of precision medicines,” Steve Cutler, Icon’s CEO, said in a statement.

RELATED: Irish CRO Icon rolls out digital platform developed with Dimension Data

Last month, Icon adopted a new digital platform developed with Dimension Data that was designed to enhance efficiency and productivity of its client’s drug and medical device pipelines. The platform was rolled out throughout the CRO to help support digital trials and patient interactions.

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.